Document is current

Article History

Received: 18 February 2019

Accepted: 13 April 2019

First Online: 25 April 2019

Compliance with ethical standards

:

: This research was partly supported by Bristol-Myers Squibb, who generously provided anti-CXCR4 and anti-PD-1 antibodies.

: <i>Michael Lim, MD</i> Research support: Arbor, Aegenus, Altor, BMS, Accuray, DNAtrix. Consultant: Tocagen, SQZ Technologies, VBI. Non-research: Consultant - Stryker, Baxter.

: <i>Henry Brem, MD</i> Research support: Arbor Pharmaceuticals, Bristol-Myers Squibb, and Accurexa. Consultant: AsclepiX Therapeutics, Celsion-EGEN, Perosphere Inc., StemGen, Accelerating Combination Therapies, Camden Partners, LikeMinds, Inc, Acuity Bio Corp.

: <i>Drew Pardoll, MD, PhD</i> Grants and Research support: Bristol-Myers Squibb, Melanoma Research Alliance. Consultant: Five Prime Therapeutics, Aduro, Compugen, GlaxoSmithKline, Medimmune/AstraZeneca, Merck, Potenza Therapeutics, Sanofi, Tizona, DNatrix, Amgen, Rock Springs Capital, Immunomic Therapeutics, Janssen, Astellas, WindMill Therapeutics, Bayer. Patents: patent for biomarkers useful for determining response to PD-1 blockade pending, patent for cancer therapy via combination of epigenetic modulation and immune modulation pending, patent for method of preventing organ transplant rejections using agonists to PD-1 checkpoint pathway pending, patent for cancer immunotherapy pending, patent for compositions and methods for targeting activin signaling to treat cancer pending, patent for combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies pending, patent for combination of immunotherapy with local chemotherapy for the treatment of malignancies pending, patent for inhibition of YAP for breaking tumor immune tolerance pending, patent for compositions and methods for cancer immunotherapy licensed to Aduro Biotech, and a patent for T cell regulation licensed to Bristol- Myers-Squibb.